BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785-790. [PMID: 14569211 DOI: 10.1097/00002281-200311000-00017] [Cited by in Crossref: 185] [Cited by in F6Publishing: 152] [Article Influence: 10.9] [Reference Citation Analysis]
Number Citing Articles
1 Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis. 2005;46:754-759. [PMID: 16183432 DOI: 10.1053/j.ajkd.2005.06.024] [Cited by in Crossref: 119] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
2 Dicarlo JB, Gupta EA, Solomon AR. A pediatric case of nephrogenic fibrosing dermopathy: Improvement after combination therapy. Journal of the American Academy of Dermatology 2006;54:914-6. [DOI: 10.1016/j.jaad.2006.01.023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
3 Al Habeeb A, Partington S, Rosenthal D, Salama S. Skin Thickening in a Hemodialysis Patient: A Case of Nephrogenic Fibrosing Dermopathy. J Cutan Med Surg 2009;13:110-4. [DOI: 10.2310/7750.2008.07085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
5 Gulati A, Harwood CA, Raftery M, Cerio R, Ashman N, Proby CA. Magnetic resonance imaging with gadolinium enhancement in renal failure: a need for caution. International Journal of Dermatology 2008;47:947-9. [DOI: 10.1111/j.1365-4632.2008.03655.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Introcaso CE, Hivnor C, Cowper S, Werth VP. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol. 2007;46:447-452. [PMID: 17472669 DOI: 10.1111/j.1365-4632.2007.03301.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
7 Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:856-63. [PMID: 18952698 DOI: 10.1093/ndt/gfn593] [Cited by in Crossref: 108] [Cited by in F6Publishing: 78] [Article Influence: 8.3] [Reference Citation Analysis]
8 Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584-93. [PMID: 18220317 DOI: 10.1002/path.2311] [Cited by in Crossref: 98] [Cited by in F6Publishing: 80] [Article Influence: 7.5] [Reference Citation Analysis]
9 Kesava Raju CS, Cossmer A, Scharf H, Panne U, Lück D. Speciation of gadolinium based MRI contrast agents in environmental water samples using hydrophilic interaction chromatography hyphenated with inductively coupled plasma mass spectrometry. J Anal At Spectrom 2010;25:55-61. [DOI: 10.1039/b919959d] [Cited by in Crossref: 40] [Cited by in F6Publishing: 2] [Article Influence: 3.6] [Reference Citation Analysis]
10 Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016;51:701-705. [PMID: 26885631 DOI: 10.1097/rli.0000000000000259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
11 Cowper SE. Nephrogenic systemic fibrosis: an overview. J Am Coll Radiol. 2008;5:23-28. [PMID: 18180005 DOI: 10.1016/j.jacr.2007.08.013] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
12 Francès C, Senet P, Lipsker D. Fibrose systémique néphrogénique. La Revue de Médecine Interne 2011;32:358-62. [DOI: 10.1016/j.revmed.2009.07.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
13 Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008;21:135-9. [PMID: 18226001 DOI: 10.1111/j.1525-139X.2007.00406.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
14 Sanchez-Ross M, Snyder R, Colome-Grimmer MI, Blumberg M, Huttenbach Y, Raimer S. Nephrogenic fibrosing dermopathy in a patient with systemic lupus erythematosus and acute lupus nephritis. Pediatr Dermatol 2007;24:E36-9. [PMID: 17958777 DOI: 10.1111/j.1525-1470.2007.00437.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
15 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
16 Housseini AM, Bozlar U, Schmitt TM, Bonatti H, Arslan B, Turba UC, Khalil TH, Hagspiel KD. Comparison of three-dimensional rotational angiography and digital subtraction angiography for the evaluation of the liver transplants. Clinical Imaging 2009;33:102-9. [DOI: 10.1016/j.clinimag.2008.06.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-75. [PMID: 18501784 DOI: 10.1053/j.ajkd.2007.12.036] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
18 Kintossou R, D’incan M, Chauveau D, Bens G, Franck F, Dauplat M, Viraben R, Déchelotte P, Souteyrand P. Dermopathie néphrogénique fibrosante traitée par photochimiothérapie extracorporelle : rôle du gadolinium ? Annales de Dermatologie et de Vénéréologie 2007;134:667-71. [DOI: 10.1016/s0151-9638(07)91830-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zvaifler NJ. Relevance of the stroma and epithelial-mesenchymal transition (EMT) for the rheumatic diseases. Arthritis Res Ther 2006;8:210. [PMID: 16689999 DOI: 10.1186/ar1963] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
20 Levine JM, Taylor RA, Elman LB, Bird SJ, Lavi E, Stolzenberg ED, McGarvey ML, Asbury AK, Jimenez SA. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569-77. [PMID: 15389718 DOI: 10.1002/mus.20153] [Cited by in Crossref: 91] [Cited by in F6Publishing: 71] [Article Influence: 5.4] [Reference Citation Analysis]
21 Saxena SK, Sharma M, Patel M, Oreopoulos D. Nephrogenic systemic fibrosis: an emerging entity. Int Urol Nephrol 2008;40:715-24. [PMID: 18418727 DOI: 10.1007/s11255-008-9361-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
22 Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258-263. [PMID: 17699422 DOI: 10.2215/cjn.03250906] [Cited by in Crossref: 108] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
23 Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan). Investigative Radiology 2007;42:139-45. [DOI: 10.1097/01.rli.0000253505.88945.d5] [Cited by in Crossref: 178] [Cited by in F6Publishing: 141] [Article Influence: 12.7] [Reference Citation Analysis]
24 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Mathur K, Morris S, Deighan C, Green R, Douglas KW. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher 2008;23:144-50. [PMID: 18633995 DOI: 10.1002/jca.20170] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
26 Silberzweig JI, Chung M. Removal of gadolinium by dialysis: review of different strategies and techniques. J Magn Reson Imaging 2009;30:1347-9. [PMID: 19937933 DOI: 10.1002/jmri.21981] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
27 Saab G, Cheng S. Nephrogenic systemic fibrosis: a nephrologist's perspective. Hemodial Int 2007;11 Suppl 3:S2-6. [PMID: 17897106 DOI: 10.1111/j.1542-4758.2007.00222.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
28 Cowper SE. Nephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium. Advances in Dermatology 2007;23:131-54. [DOI: 10.1016/j.yadr.2007.07.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
29 Maletz KL, Ennis RD, Ostenson J, Pevsner A, Kagen A, Wernick I. Comparison of CT and MR–CT Fusion for Prostate Post-Implant Dosimetry. International Journal of Radiation Oncology*Biology*Physics 2012;82:1912-7. [DOI: 10.1016/j.ijrobp.2011.01.064] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
30 Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clinics in Dermatology 2006;24:374-92. [DOI: 10.1016/j.clindermatol.2006.07.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
31 Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157. [PMID: 17267695 DOI: 10.1148/radiol.2431062144] [Cited by in Crossref: 715] [Cited by in F6Publishing: 544] [Article Influence: 51.1] [Reference Citation Analysis]
32 Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion in Rheumatology 2006;18:614-7. [DOI: 10.1097/01.bor.0000245725.94887.8d] [Cited by in Crossref: 121] [Cited by in F6Publishing: 88] [Article Influence: 8.1] [Reference Citation Analysis]
33 Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress?: Update on nephrogenic systemic fibrosis. International Journal of Dermatology 2011;50:659-66. [DOI: 10.1111/j.1365-4632.2010.04851.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
34 Panesar M, Banerjee S, Barone GW. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation: Nephrogenic systemic fibrosis. Clinical Transplantation 2008;22:803-8. [DOI: 10.1111/j.1399-0012.2008.00886.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
35 Swaminathan S, Leung N. Nephrogenic fibrosing dermopathy: lessons from the past. Int J Dermatol 2006;45:639-41. [PMID: 16796618 DOI: 10.1111/j.1365-4632.2006.02837.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
36 Deo A, Fogel M, Cowper SE. Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure. CJASN 2007;2:264-7. [DOI: 10.2215/cjn.03921106] [Cited by in Crossref: 200] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
37 Martin DR. Nephrogenic Systemic Fibrosis and Gadolinium-Enhanced Magnetic Resonance Imaging: Does a US Food and Drug Administration Alert Influence Practice Patterns in CKD? American Journal of Kidney Diseases 2010;56:427-30. [DOI: 10.1053/j.ajkd.2010.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
38 Martin DR, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, Martin PA, Chapman AB, Ray GL, Larsen CP, Pearson TC. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010;31:440-6. [PMID: 20099361 DOI: 10.1002/jmri.22024] [Cited by in Crossref: 84] [Cited by in F6Publishing: 64] [Article Influence: 7.6] [Reference Citation Analysis]
39 Mendichovszky IA, Marks SD, Simcock CM, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol. 2008;38:489-496; quiz 602-603. [PMID: 17943276 DOI: 10.1007/s00247-007-0633-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
40 Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, Singh S, Fuchsjäger M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 2012;81:2562-7. [PMID: 22304979 DOI: 10.1016/j.ejrad.2011.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
41 Latus J, Kimmel M, Ott G, Ting E, Alscher MD, Braun N. Early stages of calciphylaxis: are skin biopsies the answer? Case Rep Dermatol 2011;3:201-5. [PMID: 22110432 DOI: 10.1159/000333007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
42 Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238-249. [PMID: 16461069 DOI: 10.1016/j.semarthrit.2005.08.002] [Cited by in Crossref: 194] [Cited by in F6Publishing: 155] [Article Influence: 12.9] [Reference Citation Analysis]
43 Chrysochou C, Power A, Shurrab AE, Husain S, Moser S, Lay J, Salama AD, Kalra PA. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol. 2010;5:484-489. [PMID: 20093350 DOI: 10.2215/cjn.06580909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
44 Krous HF, Breisch E, Chadwick AE, Pinckney L, Malicki DM, Benador N. Nephrogenic Systemic Fibrosis with Multiorgan Involvement in a Teenage Male after Lymphoma, Ewing's Sarcoma, End-Stage Renal Disease, and Hemodialysis. Pediatr Dev Pathol 2007;10:395-402. [DOI: 10.2350/06-05-0093.1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
45 Juluru K, Vogel-Claussen J, Macura KJ, Kamel IR, Steever A, Bluemke DA. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics. 2009;29:9-22. [PMID: 19019996 DOI: 10.1148/rg.291085072] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
46 Deng A, Martin DB, Spillane A, Chwalek J, St Surin-Lord S, Brooks S, Petrali J, Sina B, Gaspari A, Kao G. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol 2010;37:204-10. [PMID: 19341434 DOI: 10.1111/j.1600-0560.2009.01301.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
47 Deng AC, Bilu DM, Sina B, Gaspari A. Localized nephrogenic fibrosing dermopathy: Aberrant dermal repairing? Journal of the American Academy of Dermatology 2008;58:336-9. [DOI: 10.1016/j.jaad.2007.10.491] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
48 Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol 2017;53:306-36. [PMID: 28712039 DOI: 10.1007/s12016-017-8625-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 21.0] [Reference Citation Analysis]
49 Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: An update. Curr Rheumatol Rep 2006;8:151-7. [DOI: 10.1007/s11926-006-0056-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
50 Rota E, Nallino MG, Bainotti S, Formica M. Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder. Rheumatol Int 2010;30:1389-91. [PMID: 19693506 DOI: 10.1007/s00296-009-1083-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Madke B, Khopkar U. Nephrogenic systemic fibrosis. Indian Dermatol Online J 2011;2:51-6. [PMID: 23130224 DOI: 10.4103/2229-5178.85990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
52 Crawford JR, Pilling D, Gomer RH. FcγRI mediates serum amyloid P inhibition of fibrocyte differentiation. J Leukoc Biol 2012;92:699-711. [PMID: 22493081 DOI: 10.1189/jlb.0112033] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
53 Mayr M, Burkhalter F, Bongartz G. Nephrogenic systemic fibrosis: Clinical spectrum of disease. J Magn Reson Imaging 2009;30:1289-97. [DOI: 10.1002/jmri.21975] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
54 Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Rev Nephrol 2007;3:111-5. [DOI: 10.1038/ncpneph0373] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
55 Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008;23:2121-9. [PMID: 18543004 DOI: 10.1007/s00467-008-0862-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
56 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 23] [Article Influence: 6.9] [Reference Citation Analysis]
57 Hidalgo Parra I, Torre A, Galimberti G, Rosa-Diez G, Malieni D, Kowalczuk A, Galimberti R. Nephrogenic fibrosing dermopathy. J Eur Acad Dermatol Venereol 2008;22:875-6. [PMID: 18462299 DOI: 10.1111/j.1468-3083.2007.02410.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Gilliet M, Cozzio A, Burg G, Nestle F. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005;152:531-6. [DOI: 10.1111/j.1365-2133.2005.06434.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
59 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
60 Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129-1139. [PMID: 18806155 DOI: 10.2214/ajr.08.1038.1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 27] [Article Influence: 11.8] [Reference Citation Analysis]
61 Schäd SG, Heitland P, Kühn-velten WN, Gross GE, Jonas L. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure: Gadolinium in nephrogenic fibrosis. J Cutan Pathol 2013;40:935-44. [DOI: 10.1111/cup.12214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
62 Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008;190:1060-8. [PMID: 18356456 DOI: 10.2214/AJR.07.2822] [Cited by in Crossref: 112] [Cited by in F6Publishing: 24] [Article Influence: 8.6] [Reference Citation Analysis]
63 High WA, Ranville JF, Brown M, Punshon T, Lanzirotti A, Jackson BP. Gadolinium deposition in nephrogenic systemic fibrosis: An examination of tissue using synchrotron x-ray fluorescence spectroscopy. Journal of the American Academy of Dermatology 2010;62:38-44. [DOI: 10.1016/j.jaad.2009.07.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
64 Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006;21:1307-11. [DOI: 10.1007/s00467-006-0174-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
65 Michaely H, Thomsen H, Reiser M, Schoenberg S. Nephrogene systemische Fibrose (NSF) – Implikationen für die Radiologie. Radiologe 2007;47:785-93. [DOI: 10.1007/s00117-007-1537-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
66 Jiménez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, Haddad R, Shanahan JC. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660-6. [PMID: 15334482 DOI: 10.1002/art.20362] [Cited by in Crossref: 165] [Cited by in F6Publishing: 128] [Article Influence: 9.7] [Reference Citation Analysis]
67 Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep. 2006;8:145-150. [PMID: 16569374 DOI: 10.1007/s11926-006-0055-x] [Cited by in Crossref: 172] [Cited by in F6Publishing: 163] [Article Influence: 11.5] [Reference Citation Analysis]
68 McKoy JM, Laumann A, Samaras A, Lacouture M, West D, Raisch D, Obadina E, Fajolu O, Reilly L, Bennett CL. Gadolinium-associated nephrogenic systemic fibrosis. Community Oncol 2008;5:325-6. [PMID: 19920874 DOI: 10.1016/s1548-5315(11)70463-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Rosenkranz AR, Grobner T, Mayer GJ. Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? Wien Klin Wochenschr 2007;119:271-5. [DOI: 10.1007/s00508-007-0801-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
70 Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425-2432. [PMID: 17711550 DOI: 10.1111/j.1600-6143.2007.01941.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
71 Bridges MD, St. Amant BS, Mcneil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM. High-Dose Gadodiamide for Catheter Angiography and CT in Patients With Varying Degrees of Renal Insufficiency: Prevalence of Subsequent Nephrogenic Systemic Fibrosis and Decline in Renal Function. American Journal of Roentgenology 2009;192:1538-43. [DOI: 10.2214/ajr.07.3895] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
72 Satter EK, Metcalf JS, Maize JC. Can scleromyxedema be differentiated from nephrogenic fibrosing dermatopathy by the distribution of the infiltrate? J Cutan Pathol 2006;33:756-9. [DOI: 10.1111/j.1600-0560.2006.00520.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
73 Martin DR. Nephrogenic systemic fibrosis. Pediatr Radiol. 2008;38 Suppl 1:S125-S129. [PMID: 15168803 DOI: 10.1007/s00247-007-0589-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
74 Varjú C, Kumánovics G, Czirják L, Matucci-Cerinic M, Minier T. Sclerodermalike syndromes: Great imitators. Clin Dermatol 2020;38:235-49. [PMID: 32513403 DOI: 10.1016/j.clindermatol.2019.10.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
75 Panda S, Bandyopadhyay D, Tarafder A. Nephrogenic fibrosing dermopathy: a series in a non-Western population. J Am Acad Dermatol 2006;54:155-9. [PMID: 16384776 DOI: 10.1016/j.jaad.2005.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
76 Pilling D, Cox N, Vakil V, Verbeek JS, Gomer RH. The long pentraxin PTX3 promotes fibrocyte differentiation. PLoS One 2015;10:e0119709. [PMID: 25774777 DOI: 10.1371/journal.pone.0119709] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
77 Anavekar NS, Chong AH, Norris R, Dowling J, Goodman D. Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient: Nephrogenic systemic fibrosis. Australasian Journal of Dermatology 2008;49:44-7. [DOI: 10.1111/j.1440-0960.2007.00420.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
78 Penfield JG, Reilly RF. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007;3:654-668. [PMID: 18033225 DOI: 10.1038/ncpneph0660] [Cited by in Crossref: 241] [Cited by in F6Publishing: 194] [Article Influence: 18.5] [Reference Citation Analysis]
79 George V, Tammisetti VS, Surabhi VR, Shanbhogue AK. Chronic Fibrosing Conditions in Abdominal Imaging. RadioGraphics 2013;33:1053-80. [DOI: 10.1148/rg.334125081] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 4.9] [Reference Citation Analysis]
80 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
81 Ishiguchi T, Takahashi S. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 2010;10:133-45. [PMID: 20945944 DOI: 10.2165/11539140-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
82 Pilling D, Gomer RH. The Development of Serum Amyloid P as a Possible Therapeutic. Front Immunol 2018;9:2328. [PMID: 30459752 DOI: 10.3389/fimmu.2018.02328] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
83 Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. Br J Radiol 2014;87:20140307. [PMID: 25230161 DOI: 10.1259/bjr.20140307] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
84 Kurtkoti J, Snow T, Hiremagalur B. Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology (Carlton) 2008;13:235-41. [PMID: 18221255 DOI: 10.1111/j.1440-1797.2007.00912.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
85 Chewning RH, Murphy KJ. Gadolinium-based Contrast Media and the Development of Nephrogenic Systemic Fibrosis in Patients with Renal Insufficiency. Journal of Vascular and Interventional Radiology 2007;18:331-3. [DOI: 10.1016/j.jvir.2007.01.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
86 Sreenarasimhaiah VP, Brown WW, Cortese C, Sirintrapun J, Janney C, Philipneri M, Gellens M, Flynn L, Joseph A, Bastani B. A report on four new cases of nephrogenic fibrosing dermopathy in chronic hemodialysis patients. Hemodialysis International 2004;8:404-8. [DOI: 10.1111/j.1492-7535.2004.80418.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. Journal of the American Academy of Dermatology 2006;54:S31-4. [DOI: 10.1016/j.jaad.2005.04.024] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
88 Sato T, Tamada T, Watanabe S, Nishimura H, Kanki A, Noda Y, Higaki A, Yamamoto A, Ito K. Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Radiol med 2015;120:557-62. [DOI: 10.1007/s11547-014-0492-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Pan D, Senpan A, Caruthers SD, Williams TA, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem Commun (Camb) 2009;:3234-6. [PMID: 19587924 DOI: 10.1039/b902875g] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
90 Alibek S, Cavallaro A, Aplas A, Uder M, Staatz G. Diffusion Weighted Imaging of Pediatric and Adolescent Malignancies with Regard to Detection and Delineation: Initial Experience2. Academic Radiology 2009;16:866-71. [DOI: 10.1016/j.acra.2009.01.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
91 Ruiz-genao DP, Pascual-lopez MP, Fraga S, Aragues M, Garcia-diez A. Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol 2005;32:172-5. [DOI: 10.1111/j.0303-6987.2005.00277.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
92 Cheung PPM, Dorai Raj AK. Nephrogenic fibrosing dermopathy: a new clinical entity mimicking scleroderma. Internal Medicine Journal 2007;37:139-41. [DOI: 10.1111/j.1445-5994.2007.01252.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
93 Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191-199. [PMID: 18325705 DOI: 10.1016/j.ejrad.2008.01.016] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
94 Brambilla S, Valaperta S, Graziani G, Montanelli A. Gadolinium and lanthanum: A iatrogenic transmetallation? Clinical Biochemistry 2008;41:1029-33. [DOI: 10.1016/j.clinbiochem.2008.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
95 Kielstein JT, Schiffer M. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. Internist (Berl) 2010;51:39-44. [PMID: 20033388 DOI: 10.1007/s00108-009-2408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
96 Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE. Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis. Appl Immunohistochem Mol Morphol 2010;18:448-52. [PMID: 20485155 DOI: 10.1097/PAI.0b013e3181de372e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
97 Chang P, Saddleton E, Laumann AE, Schmitz B, West DP, Belknap SM, Parthasarathy S, Edwards BJ, McKoy JM, Miller FH. Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function. Acad Radiol 2012;19:1181-5. [PMID: 22831822 DOI: 10.1016/j.acra.2012.04.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
98 Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM. Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol 2013;183:796-807. [PMID: 23867799 DOI: 10.1016/j.ajpath.2013.06.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
99 Cox N, Pilling D, Gomer RH. Serum amyloid P: a systemic regulator of the innate immune response. J Leukoc Biol 2014;96:739-43. [PMID: 24804675 DOI: 10.1189/jlb.1MR0114-068R] [Cited by in Crossref: 52] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
100 Chinthalapati Siva Kesava Raju, Lück D, Scharf H, Jakubowski N, Panne U. A novel solid phase extraction method for pre-concentration of gadolinium and gadolinium based MRI contrast agents from the environment. J Anal At Spectrom 2010;25:1573. [DOI: 10.1039/c003251d] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
101 Perazella MA. Nephrogenic Systemic Fibrosis, Kidney Disease, and Gadolinium: Is There a Link?: Figure 1. CJASN 2007;2:200-2. [DOI: 10.2215/cjn.00030107] [Cited by in Crossref: 80] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
102 Digby S, Macduff E, Blessing K, Holmes S. Nephrogenic systemic fibrosis: a histopathological study of eight cases of a recently described entity. Histopathology 2008;52:531-4. [DOI: 10.1111/j.1365-2559.2008.02947.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
103 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
104 Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 2016;25:163-9. [PMID: 27367314 DOI: 10.1097/RMR.0000000000000095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
105 Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108. [PMID: 16431890 DOI: 10.1093/ndt/gfk062] [Cited by in Crossref: 1268] [Cited by in F6Publishing: 974] [Article Influence: 84.5] [Reference Citation Analysis]
106 Kaewlai R, Abujudeh H. Nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2012;199:W17-W23. [PMID: 22733927 DOI: 10.2214/ajr.11.8144] [Cited by in Crossref: 78] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
107 Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-parker S, Martin DR. Nephrogenic systemic fibrosis: Center case review. J Magn Reson Imaging 2007;26:1198-203. [DOI: 10.1002/jmri.21136] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
108 Hazelton JM, Chiu MK, Abujudeh HH. Nephrogenic Systemic Fibrosis: A Review of History, Pathophysiology, and Current Guidelines. Curr Radiol Rep 2019;7. [DOI: 10.1007/s40134-019-0312-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
109 Weckbach S, Schoenberg SO. Whole body MR imaging in diabetes. Eur J Radiol 2009;70:424-30. [PMID: 19428209 DOI: 10.1016/j.ejrad.2009.04.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
110 Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88. [PMID: 18440117 DOI: 10.1016/j.tox.2008.03.012] [Cited by in Crossref: 114] [Cited by in F6Publishing: 87] [Article Influence: 8.8] [Reference Citation Analysis]
111 Samtleben W. [Nephrogenic systemic fibrosis]. Radiologe 2007;47:778-84. [PMID: 17717643 DOI: 10.1007/s00117-007-1545-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
112 Lewis KG, Lester BW, Pan TD, Robinson-bostom L. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol 2006;33:695-700. [DOI: 10.1111/j.1600-0560.2006.00490.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
113 Chien CC, Wang HY, Wang JJ, Kan WC, Chien TW, Lin CY, Su SB. Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment. Ren Fail 2011;33:758-64. [PMID: 21777176 DOI: 10.3109/0886022X.2011.599911] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
114 Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007;72:260-4. [PMID: 17507905 DOI: 10.1038/sj.ki.5002338] [Cited by in Crossref: 192] [Cited by in F6Publishing: 145] [Article Influence: 13.7] [Reference Citation Analysis]
115 High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21-26. [PMID: 17097388 DOI: 10.1016/j.jaad.2006.10.047] [Cited by in Crossref: 361] [Cited by in F6Publishing: 282] [Article Influence: 24.1] [Reference Citation Analysis]
116 Lim YL, Lee HY, Low SCS, Chan LP, Goh NSG, Pang SM. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 2007;32:353-8. [DOI: 10.1111/j.1365-2230.2007.02412.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
117 Chao C, Yang C, Hsiao C, Pan M, Lin C, Hsieh S. Nephrogenic Systemic Fibrosis Associated with Gadolinium Use. Journal of the Formosan Medical Association 2008;107:270-4. [DOI: 10.1016/s0929-6646(08)60147-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
118 Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007;18:2636-43. [PMID: 17855637 DOI: 10.1681/ASN.2007060645] [Cited by in Crossref: 103] [Cited by in F6Publishing: 25] [Article Influence: 7.4] [Reference Citation Analysis]
119 Kim RH, Ma L, Hayat SQ, Ahmed MM. Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis in 2 Patients With End-Stage Renal Disease on Hemodialysis: . JCR: Journal of Clinical Rheumatology 2006;12:134-6. [DOI: 10.1097/01.rhu.0000222053.47708.dd] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
120 Wang W, Lazar A. Diseases of collagen and elastic tissue. McKee's Pathology of the Skin. Elsevier; 2012. pp. 935-66. [DOI: 10.1016/b978-1-4160-5649-2.00021-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Dehoratius DM, Cowper SE. Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients: NEPHROGENIC SYSTEMIC FIBROSIS. Seminars in Dialysis 2006;19:191-4. [DOI: 10.1111/j.1525-139x.2006.00152.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
122 Manger B. Nephrogene systemische Fibrose: Medizinische Detektivarbeit im 21. Jahrhundert. Z Rheumatol 2007;66:533-5. [DOI: 10.1007/s00393-007-0186-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
123 Dupont A, Majithia V, Ahmad S, Mcmurray R. Nephrogenic Fibrosing Dermopathy, a New Mimicker of Systemic Sclerosis. The American Journal of the Medical Sciences 2005;330:192-4. [DOI: 10.1097/00000441-200510000-00007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
124 Thomsen HS. Nephrogenic Systemic Fibrosis: NEPHROGENIC SYSTEMIC FIBROSIS. Imaging Decisions MRI 2008;11:13-8. [DOI: 10.1111/j.1617-0830.2007.00110.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
125 Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175. [PMID: 17704357 DOI: 10.1148/radiol.2451070353] [Cited by in Crossref: 247] [Cited by in F6Publishing: 187] [Article Influence: 17.6] [Reference Citation Analysis]
126 Lemy AA, del Marmol V, Kolivras A, High WA, Matos C, Laporte M, Nortier JL. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience. Journal of the American Academy of Dermatology 2010;63:389-99. [DOI: 10.1016/j.jaad.2009.10.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
127 Pilling D, Tucker NM, Gomer RH. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 2006;79:1242-51. [PMID: 16543402 DOI: 10.1189/jlb.0805456] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 4.3] [Reference Citation Analysis]
128 Shin K, Granter SR, Coblyn JS, Gupta S. Progressive arm and leg stiffness in a patient with chronic renal impairment. Nat Rev Rheumatol 2008;4:557-62. [DOI: 10.1038/ncprheum0883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
129 Al-hayk K, Bertorini TE. Neuromuscular Complications in Uremics: A Review. The Neurologist 2007;13:188-96. [DOI: 10.1097/01.nrl.0000263699.53969.e9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
130 Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009;61:537-52. [PMID: 19131226 DOI: 10.1016/j.etp.2008.11.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
131 Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol 2017;31:1581-94. [PMID: 28786499 DOI: 10.1111/jdv.14466] [Cited by in Crossref: 42] [Cited by in F6Publishing: 11] [Article Influence: 10.5] [Reference Citation Analysis]
132 Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, Hanjani NM, Scott GA. Nephrogenic systemic fibrosis: A clinicopathologic study of six cases. Journal of the American Academy of Dermatology 2007;57:105-11. [DOI: 10.1016/j.jaad.2007.02.021] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
133 Cowell GW, Reid AW, Roditi GH. Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging. Insights Imaging 2012;3:495-504. [PMID: 22865510 DOI: 10.1007/s13244-012-0188-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
134 Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21:123-8. [PMID: 18226008 DOI: 10.1111/j.1525-139X.2007.00399.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
135 Riccabona M, Dacher J, Olsen ØE, Claudon M, Fotter R. Gadolinium and Nephrogenic Systemic Fibrosis. In: Fotter R, editor. Pediatric Uroradiology. Berlin: Springer Berlin Heidelberg; 2008. pp. 515-7. [DOI: 10.1007/978-3-540-33005-9_29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Ramaizel L, Sliwa JA. Rehabilitation in Nephrogenic Systemic Fibrosis. PM&R 2009;1:684-6. [DOI: 10.1016/j.pmrj.2009.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
137 Lim J, Park EA, Song YS, Lee W. Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI. Korean J Radiol 2018;19:372-80. [PMID: 29713214 DOI: 10.3348/kjr.2018.19.3.372] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
138 Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Ann Med 2007;39:42-53. [PMID: 17364450 DOI: 10.1080/07853890601098152] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
139 So K, Macquillan GC, Adams LA, Delriviere L, Mitchell A, Moody H, Wood DJ, Junckerstorff RC, Jeffrey GP. Malignant fibrous histiocytoma complicating nephrogenic systemic fibrosis post liver transplantation. Intern Med J. 2009;39:613-617. [PMID: 19769682 DOI: 10.1111/j.1445-5994.2009.01977.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
140 Shen L, Yang A, Yao P, Sun X, Chen C, Mo C, Shi L, Chen Y, Liu Q. Gadolinium promoted proliferation in mouse embryo fibroblast NIH3T3 cells through Rac and PI3K/Akt signaling pathways. Biometals 2014;27:753-62. [DOI: 10.1007/s10534-014-9769-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
141 Arian M, Zamanian A, Taheri S. Highly water-dispersible calcium lignosulfonate-capped MnO nanoparticles as a T1 MRI contrast agent with exceptional colloidal stability, low toxicity and remarkable relaxivity. RSC Adv 2019;9:40498-506. [DOI: 10.1039/c9ra09125d] [Reference Citation Analysis]
142 Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol 2006;7:237-47. [PMID: 16901184 DOI: 10.2165/00128071-200607040-00005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
143 Maloo M, Abt P, Kashyap R, Younan D, Zand M, Orloff M, Jain A, Pentland A, Scott G, Bozorgzadeh A. Nephrogenic Systemic Fibrosis Among Liver Transplant Recipients: A Single Institution Experience and Topic Update. Am J Transplant 2006;6:2212-7. [DOI: 10.1111/j.1600-6143.2006.01420.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
144 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
145 Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 2005;32:484-90. [DOI: 10.1111/j.0303-6987.2005.00365.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
146 Plamondon I, Samson C, Watters AK, Bégin LR, Côté J, Déziel C, Quérin S. La fibrose systémique néphrogénique: nouveau coup dur pour les insuffisants rénaux. Néphrologie & Thérapeutique 2007;3:152-6. [DOI: 10.1016/j.nephro.2007.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
147 Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. Semin Arthritis Rheum. 2006;35:208-210. [PMID: 16461067 DOI: 10.1016/j.semarthrit.2005.09.005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
148 Moreno-romero J, Segura S, Mascaró J, Cowper S, Julià M, Poch E, Botey A, Herrero C. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007;157:783-7. [DOI: 10.1111/j.1365-2133.2007.08067.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
149 Cowper SE. Nephrogenic Systemic Fibrosis: The Nosological and Conceptual Evolution of Nephrogenic Fibrosing Dermopathy. American Journal of Kidney Diseases 2005;46:763-5. [DOI: 10.1053/j.ajkd.2005.08.008] [Cited by in Crossref: 76] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
150 Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'malley RB, Parsons DJ, Fuller ER, Semelka RC. Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities. Radiology 2008;248:799-806. [DOI: 10.1148/radiol.2483072093] [Cited by in Crossref: 138] [Cited by in F6Publishing: 113] [Article Influence: 10.6] [Reference Citation Analysis]
151 Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008;43:65-75. [PMID: 18097279 DOI: 10.1097/RLI.0b013e31815e6277] [Cited by in Crossref: 165] [Cited by in F6Publishing: 44] [Article Influence: 12.7] [Reference Citation Analysis]
152 Kalisz KR, Davarpanah AH, Usman AA, Collins JD, Carroll TJ, Carr JC. Detection of Renal Dysfunction by Point-of-Care Creatinine Testing in Patients Undergoing Peripheral MR Angiography. American Journal of Roentgenology 2011;197:430-5. [DOI: 10.2214/ajr.10.5761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]